keyboard_arrow_right
Search keyboard_arrow_right
keyboard_arrow_left Hide
Day 2: Main Conference
search
Day 2: Main Conference
search
06:30 - 07:00
HIIT Fitness Class
Start your day right and join other TIDES Europe attendees for this morning’s HIIT fitness – strength and conditioning exercises, led by a fitness trainer. Reserve your spot today by sending your RSVP via this form: http://get.informaconnect.com/tides-europe/fitness/
Showing 1 of 1 Streams
Morning Spotlight Presentation
07:30 - 08:00
Reducing Environmental Impact During Oligonucleotide Manufacturing with AJIPHASE
- Yusaku Nomura, Ph.D. - Research Chemist, Ajinomoto
Showing 3 of 3 Streams
Oligonucleotide Track
Peptide Track
mRNA, Genome Editing and Oligo CMC Track
08:00 - 08:05
Chairperson's Remarks
- Troels Koch, PhD - Senior Vice President, Chemistry, MiNa Therapeutics
08:05 - 08:30
AOCC Click Chemistry for Oligonucleotide Therapeutic Development
- Muthiah (Mano) Manoharan, PhD - Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals
08:30 - 08:55
GalAhead™: A Proprietary GalNAc-RNAi Therapeutic Platform to Downregulate Single and Multiple Genes
- Jimmy Weterings, PhD - Vice President Research, RNA Therapeutics & Delivery, Sirnaomics
08:55 - 09:20
Controlled Sulfur-based Engineering Confers Mouldability to Phosphorothioate Antisense Oligonucleotides
- Vito Genna, PhD - Director of Nucleic Acids Department, Nostrum Biodiscovery
09:20 - 09:45
Research and Development of the Template-Directed RIG-I Agonist, TTX-RIGA, for Systemic Cancer Immunotherapy
- Zdravka Medarova, PhD - Founder and Chief Technology Officer, TransCode Therapeutics
08:00 - 08:05
Chairperson's Remarks
- Fernando Albericio, PhD - Research Professor, School of Chemistry, University of Kwazulu-Natal
08:05 - 08:30
Safety-Catch Protection in Solid-Phase Peptide Synthesis
- Fernando Albericio, PhD - Research Professor, School of Chemistry, University of Kwazulu-Natal
08:30 - 08:55
Refractive Index: A Green Holistic Tool for Greening SPPS
- Beatriz De La Torre, Ph.D. - Research Professor, Laboratory of Medicine and Med, University Of KwaZulu-Natal
08:55 - 09:20
Engineering of a Potent and Selective GLP-1 Receptor Agonist from the Secretin Backbone Using the streaMLine Platform for Accelerated Lead Generation
- Jens Christian Nielsen, Ph.D. - Principal Scientist, AI Technology, Gubra
09:20 - 09:45
Imotope Platform: Linear Synthetic Peptides to Cure Auto-immune Diseases
- Justine Siciliani - CMC Coordinator, Imcyse SA
08:00 - 08:05
Chairperson's Remarks
- Yelena Lyubarskaya, PhD - Analytical Strategy Lead, Technical Development, Moderna
08:05 - 08:30
Development of mRNA-LNP Therapeutics
- Yelena Lyubarskaya, PhD - Analytical Strategy Lead, Technical Development, Moderna
08:30 - 08:55
mRNA-based Therapy Proves Superior to the Standard of Care for Treating Hereditary Tyrosinemia 1 in a Mouse Model
- Christine Weinl-Tenbruck, Ph.D. - Senior Scientist, Dept. of Molecular Therapy, CureVac SE
08:55 - 09:20
mRNA Vaccines Potency Assays: Exploring Correlations and Gaps Between Methods
- Thibaut Willemin - Bioassay Scientist, mRNA Center of Excellence | Sanofi
09:20 - 09:45
Correlates of Protection from a mRNA Dengue Vaccine
- James Brien, Ph.D. - Assistant Professor, Saint Louis University
09:45 - 10:30
Networking Refreshment Break in Poster and Exhibit Hall
- Mina Wang, PhD - Peptide Senior Scientist, GenScript
Showing 3 of 3 Streams
Oligonucleotide Track
Peptide Track
mRNA, Genome Editing and Oligo CMC Track
10:30 - 11:00
Antisense Oligonucleotides for Eye Diseases
- Rob Collin, Ph.D. - Chief Scientific Officer, Astherna
11:00 - 11:30
Extended Nucleic Acid (exNA): A Platform Technology for Enhancing siRNA Potency in vivo
- Ken Yamada, Ph.D. - Assistant Professor, University of Massachusetts Medical School
10:30 - 11:00
Bicycles, A Flexible Antiviral Modality with Therapeutic and Prophylactic Relevance In Vivo
- Max Harman - Research Associate - Molecular Pharmacology, Bicycle Therapeutics
11:00 - 11:30
Peptide-based Targeting of FOXO4-p53 Against Scarred Cancer
- Peter de Keizer, Ph.D. - Managing Director, Founder, Cleara Biotech
10:30 - 11:00
LNP Production for mRNA Vaccines, Therapeutics and for Gene-editing: Proof-of-concept for a Versatile Process
- Thomas Vrucina - Deputy Head Liposome Technology, Polymun Scientific
11:00 - 11:30
LNP Formulation Screening, A CDMO Perspective
- Umberto Romeo - Head of R&D, Corden Pharma Caponago
Showing 3 of 3 Streams
Spotlight Presentation 1
Spotlight Presentation 2
Spotlight Presentation 3
11:35 - 12:05
QC for Oligos - From HPLC Development to GMP
- Constanze Schmies, PhD - Senior Scientist QC, Bachem AG
11:35 - 12:05
From Lab to Commercial: Oligo Development Scale-up Considerations
- George Flores - Technical Solutions Manager, Asahi Kasei Bioprocess America
11:35 - 12:05
One-step Oligonucleotide Purification with On-column 5’-DMT Cleavage Using a Novel Chromatography Resin
- Patrick Endres - Product Management EMEA, Tosoh Bioscience GmbH
12:05 - 13:25
Networking Luncheon in Poster and Exhibit Hall
- Christian Schwarz, PhD - CEO, Numaferm GmbH
Showing 3 of 3 Streams
Spotlight Presentation 1
Spotlight Presentation 2
Spotlight Presentation 3
13:25 - 13:55
Oligonucleotide Therapeutics: Manufacturing for Research and Beyond
- Katarina Stenklo - Enterprise Solutions Commercial Activation Leader, Cytiva
13:25 - 13:55
Application of PAT for Process Understanding and Control Strategy during Development and Manufacturing of Oligonucleotides
- Jale Muslehiddinoglu, PhD - Vice President of Strategic Innovation, ST Pharm
13:25 - 13:55
Impurity Analysis of Phosphoramidites for Manufacturing Oligonucleotide Therapeutics
- Gary Held - Staff Scientist, Analytical Development, Thermo Fisher Scientific
Showing 3 of 3 Streams
Oligonucleotide Track
Peptide Track
mRNA, Genome Editing & Oligo CMC Track
13:55 - 14:00
Chairperson's Remarks
- Paul Nioi, PhD - Vice President, Discovery and Translational Research, Alnylam Pharmaceuticals
14:00 - 14:30
Beyond the Liver: Extra-hepatic Targeting of RNAi Therapeutics
- Paul Nioi, PhD - Vice President, Discovery and Translational Research, Alnylam Pharmaceuticals
14:30 - 15:00
Oligonucleotide Therapies for Rare Neurological Diseases
- Hélène Tran, Ph.D. - Oligo Therapeutics Program Science Lead, Servier
13:55 - 14:00
Chairman's Remarks
- Jon Holbech Rasmussen, Ph.D. - Director, Global Development, PolyPeptide Group
14:00 - 14:30
Novel Peptide Inhibitors
- Christian Bech-Bartling - Assistant Professor, Department of Drug Design and Pharmacology, The University of Copenhagen
14:30 - 15:00
Discovery of Zilucoplan: A Potent Macrocyclic Peptide Complement Component 5 (C5) Inhibitor in Acetylcholine Receptor Antibody-positive Generalized Myasthenia Gravis
- Lihu Yang, PhD - Head of Discovery Chemistry US, UCB
13:55 - 14:00
Chairperson Remarks
- Jane Wang, Ph.D. - Executive Director of Delivery Technologies, Tessera Therapeutics
14:00 - 14:30
mRNA and LNPs for Delivery of Base Editors to Target Organs
- Luis Brito, PhD - Vice President, Delivery Platform, Beam Therapeutics
14:30 - 15:00
Delivering Mobile Genetic Elements to Write DNA Sequences with RNA
- Jane Wang, Ph.D. - Executive Director of Delivery Technologies, Tessera Therapeutics
15:00 - 15:30
Networking Refreshment Break in Poster and Exhibit Hall
Showing 3 of 3 Streams
Oligonucleotide Track
Peptide Track
mRNA, Genome Editing & Oligo CMC Track
15:30 - 16:00
TfR-targeted Functional Delivery of Oligonucleotides to CNS Tissues by Local and Systemic Administration
- Guillaume Jacquot, PharmD, Ph.D - Program Director, Brain & Tissue Delivery of Oligonucleotides, VECT-HORUS S.A.S.
16:00 - 16:30
Eplontersen in Hereditary, Tranthyretin-mediated Polyneuropathy: Week 66 Final Analysis of the Phase 3 NEURO-TTRansform Study
- Nicholas Viney - Executive Director, Clinical Development, Ionis Pharmaceuticals
16:30 - 17:00
BMN 351, A Next-generation Phosphorothioate Antisense Oligonucleotide That Targets A Novel Upstream, Splice Enhancer Site and Induces Exon 51 Skipping in Human Dystrophin Pre-mRNA
- Soumi Gupta, Ph.D. - Senior Director, Clinical Immunology, BioMarin Pharmaceutical
15:30 - 16:00
Towards Sustainable Peptide Manufacturing: Greening Solid Phase Peptide Synthesis (SPPS) for Large Scale Production
- Tharwat Mohy El Dine, Ph.D. - Innovation Scientist, PolyPeptide Group
16:00 - 16:30
Towards Greener Peptide Production for Phase 3 and Market
- Daniel Sejer Pedersen, PhD - Chemical Development Specialist, Chemical Development, Novo Nordisk
16:30 - 17:00
Peptide Validation Strategy to Support Commercial Manufacturing and Distribution
- Dave Garman, PhD - Chief Technology Officer, NoNO, Inc.
15:30 - 16:00
Development and Application of Graph Neural Networks to Design Guide Oligonucleotides that Promote RNA Editing
- Matt Maciejewski, Ph.D. - Vice President and Head of Data Science, Korro Bio
16:00 - 16:30
Advancements in Oligonucleotide Sequencing and Impurity Analysis
- Gangani Silva, PhD - Associate Director, Analytical Development, Nitto Avecia
16:30 - 17:00
EMA Experience and Ongoing Activities Related to mRNA Technology
- Brian Dooley - Pharmaceutical Quality Senior Specialist, European Medicines Agency
17:00 - 19:00
Evening Networking Reception In Amsterdam
19:00 - 19:05
Close of Day Two
Get the Latest Event Updates
Sign up to get the latest event updates and information.